Insights Into the Antigenic Repertoire of Unclassified Synaptic Antibodies
ABSTRACT Objective We sought to characterize the sixth most common finding in our neuroimmunological laboratory practice (tissue assay‐observed unclassified neural antibodies [UNAs]), combining protein microarray and phage immunoprecipitation sequencing (PhIP‐Seq). Methods Patient specimens (258; 133 serums; 125 CSF) meeting UNA criteria were profiled;
Michael Gilligan +22 more
wiley +1 more source
Theranostic application of radiolabeled HER2-targeting single-domain antibodies (RAD202) in preclinical setting. [PDF]
Altunay B +9 more
europepmc +1 more source
ABSTRACT Mutations in myelin regulatory factor (MYRF) are linked to demyelinating disorders. We report a 38‐year‐old male who developed acute symmetric leukoencephalopathy mimicking a stroke following an influenza A virus infection. While clinical symptoms markedly improved with corticosteroids, MRI revealed persistent white matter lesions, contrasting
Jinghan Hu +5 more
wiley +1 more source
Improving the solubility of single domain antibodies using VH-like hallmark residues. [PDF]
Uto Y +9 more
europepmc +1 more source
Enteric pharmacokinetics of monomeric and multimeric camelid nanobody single-domain antibodies. [PDF]
Debatis M +9 more
europepmc +1 more source
ABSTRACT Neuromyelitis Optica Spectrum Disorder (NMOSD) is a chronic autoimmune neuroinflammatory disease, typically characterized by antibodies against aquaporin 4 (AQP4‐IgG) or myelin oligodendrocyte glycoprotein (MOG‐IgG). Simultaneous seropositivity for both antibodies in a single patient is exceedingly rare.
Yeting Luo, Shuhua Xie, Xianghong Liu
wiley +1 more source
From discovery to the clinic: structural insights, engineering options, clinical, and 'next wave' applications of camelid-derived single-domain antibodies. [PDF]
Evers A +3 more
europepmc +1 more source
Targeted Alpha Therapy (TAT) with Single-Domain Antibodies (Nanobodies). [PDF]
Hurley K, Cao M, Huang H, Wang Y.
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Demonstration of <i>in vivo</i> efficacy, cryo-EM-epitope identification, and breadth of two anti-alphavirus bispecific single domain antibodies. [PDF]
Gardner CL +14 more
europepmc +1 more source

